Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data from ...

Azacitidine and decitabine belong to a class of antineoplastic agents known as DNA methyltransferase inhibitors (DMTIs). Each is paired with cedazuridine, a cytidine deaminase inhibitor, to help the ...

Popular weight-loss drugs “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related ...

Prof. Ulrich Kelber warns of Germany's decline in data protection. He sharply criticizes the security and implementation of ...

A 15-year effort by Leona Helmsley’s philanthropy to improve rural health care offers lessons for other grant makers.

A study published in The BMJ linked skipping first and subsequent mammograms to a higher chance of dying from breast cancer.

In recent weeks, AbbVie has reported positive clinical and regulatory updates across several franchises, including strong ...

Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive ...

Ernexa is advancing a best-in-class approach using synthetic, allogeneic iMSCs to provide a scalable, off-the-shelf treatment without needing patient-specific cell harvesting. The Company continues to ...

The American Cancer Society has recently updated cervical screening guidelines for HPV and cervical cancer. Here are the main changes.

The ASH oral presentation today reports data from the ongoing dose escalation and dose expansion parts of the CARDINAL study of TERN-701 in patients with previously treated CML. As of the September 13 ...

Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus ...